EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice

Quan Zhang, Miao Wang, Chunle Han, Zhijun Wen, Xiaozhu Meng, Dongli Qi, Na Wang, Huanqing Du, Jianhong Wang, Lu Lu, Xiaohu Ge

Vaccines · 16.03.2023 · 11 (3) · 673

DOI: 10.3390/vaccines11030673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 16.03.2023. Verfasst von Quan Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Tingo Exosomes Technology Co., Ltd., Tianjin 300301, China. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tingo Exosomes Technology Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has presented numerous challenges to global health. Vaccines, including lipid—based nanoparticle mRNA, inactivated virus, and recombined protein, have been used to prevent SARS-CoV-2 infections in clinics and have been immensely helpful in controlling the pandemic. Here, we present and assess an oral mRNA vaccine based on bovine-milk-derived exosomes (milk-exos), which encodes the SARS-CoV-2 receptor-binding domain (RBD) as an immunogen. The results indicate that RBD mRNA delivered by milk-derived exosomes can produce secreted RBD peptides in 293 cells in vitro and stimulates neutralizing antibodies against RBD in mice. These results indicate that SARS-CoV-2 RBD mRNA vaccine loading with bovine-milk-derived exosomes is an easy, cheap, and novel way to introduce immunity against SARS-CoV-2 in vivo. Additionally, it also can work as a new oral delivery system for mRNA.

Schlagwörter

Stichwörter der Autor:innen

SARS-CoV-2bovine-milk-derived exosomesmRNAneutralizing antibodiesoral vaccinesreceptor-binding domain

Autor:innen und Institutionen

  • Tingo Exosomes Technology Co., Ltd., Tianjin 300301, China.
  • Tingo Regenerative Medicine Technology Co., Ltd., Tianjin 300301, China.

Förderung

  • Tingo Exosomes Technology Co., Ltd.

Zitieren

APA

Zhang, Q., Wang, M., Han, C., Wen, Z., Meng, X., Qi, D., Wang, N., Du, H., Wang, J., Lu, L., & Ge, X. (2023). Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice. Vaccines, 11(3), 673. https://doi.org/10.3390/vaccines11030673

Vancouver

Zhang Q, Wang M, Han C, Wen Z, Meng X, Qi D, et al. Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice. Vaccines. 2023;11(3):673. doi:10.3390/vaccines11030673

BibTeX
@article{Zhang2023,
  author = {Zhang, Quan and Wang, Miao and Han, Chunle and Wen, Zhijun and Meng, Xiaozhu and Qi, Dongli and Wang, Na and Du, Huanqing and Wang, Jianhong and Lu, Lu and Ge, Xiaohu},
  title = {Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {3},
  pages = {673},
  doi = {10.3390/vaccines11030673}
}
Kostenlos starten →